Oskar Hansson

Research interests

Publications

• European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders

  The Lancet Neurology · 2024 · https://doi.org/10.1016/s1474-4422(23)00447-7

• Biomarker-based staging of Alzheimer disease: rationale and clinical applications

  Nature Reviews Neurology · 2024 · https://doi.org/10.1038/s41582-024-00942-2

• Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup

  Alzheimer s & Dementia · 2024 · https://doi.org/10.1002/alz.13859

• A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases

  Nature Aging · 2023 · https://doi.org/10.1038/s43587-023-00471-5

• Donanemab in Early Symptomatic Alzheimer Disease

  JAMA · 2023 · https://doi.org/10.1001/jama.2023.13239

• Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets

  Nature Immunology · 2023 · https://doi.org/10.1038/s41590-023-01588-w

• Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials

  The Lancet Neurology · 2022 · https://doi.org/10.1016/s1474-4422(22)00168-5

• Brain charts for the human lifespan

  Nature · 2022 · https://doi.org/10.1038/s41586-022-04554-y

• Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease

  The Journal of Prevention of Alzheimer s Disease · 2022 · https://doi.org/10.14283/jpad.2022.30

• Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum

  JAMA Neurology · 2022 · https://doi.org/10.1001/jamaneurol.2021.5216

• The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease

  Alzheimer s & Dementia · 2022 · https://doi.org/10.1002/alz.12756

• Blood-based biomarkers for Alzheimer's disease: towards clinical implementation

  The Lancet Neurology · 2021 · https://doi.org/10.1016/s1474-4422(21)00361-6

• Four distinct trajectories of tau deposition identified in Alzheimer’s disease

  Nature Medicine · 2021 · https://doi.org/10.1038/s41591-021-01309-6

• The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease

  Alzheimer s & Dementia · 2021 · https://doi.org/10.1002/alz.12283

• Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease

  Brain · 2021 · https://doi.org/10.1093/brain/awab223

• Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease

  JAMA Neurology · 2021 · https://doi.org/10.1001/jamaneurol.2021.1858

• Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study

  The Lancet Neurology · 2021 · https://doi.org/10.1016/s1474-4422(21)00214-3

• Biomarkers for neurodegenerative diseases

  Nature Medicine · 2021 · https://doi.org/10.1038/s41591-021-01382-x

• A multicentre validation study of the diagnostic value of plasma neurofilament light

  Nature Communications · 2021 · https://doi.org/10.1038/s41467-021-23620-z

• LifeTime and improving European healthcare through cell-based interceptive medicine

  Nature · 2020 · https://doi.org/10.1038/s41586-020-2715-9

• Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

  JAMA · 2020 · 10.1001/jama.2020.12134

• Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease

  JAMA Neurology · 2020 · https://doi.org/10.1001/jamaneurol.2019.5154

• Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

  Nature Medicine · 2020 · 10.1038/s41591-020-0755-1

• Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

  The Lancet Neurology · 2020 · 10.1016/s1474-4422(20)30071-5

• Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

  Alzheimer s Research & Therapy · 2019 · https://doi.org/10.1186/s13195-019-0485-0

• Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study

  The Lancet Neurology · 2019 · https://doi.org/10.1016/s1474-4422(19)30283-2

• CSF and blood biomarkers for Parkinson's disease

  The Lancet Neurology · 2019 · https://doi.org/10.1016/s1474-4422(19)30024-9

• Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology

  JAMA Neurology · 2019 · 10.1001/jamaneurol.2019.1534

• Discriminative Accuracy of [ 18 F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders

  JAMA · 2018 · https://doi.org/10.1001/jama.2018.12917

• Prevalence of amyloid‐β pathology in distinct variants of primary progressive aphasia

  Annals of Neurology · 2018 · https://doi.org/10.1002/ana.25333

• CSF biomarkers of Alzheimer's disease concord with amyloid‐β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts

  Alzheimer s & Dementia · 2018 · https://doi.org/10.1016/j.jalz.2018.01.010

• Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity

  Nature Communications · 2017 · https://doi.org/10.1038/s41467-017-01150-x

• Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers

  The Lancet Neurology · 2017 · https://doi.org/10.1016/s1474-4422(17)30159-x

• Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia

  JAMA Psychiatry · 2017 · https://doi.org/10.1001/jamapsychiatry.2017.3391

• Plasma β-amyloid in Alzheimer’s disease and vascular disease

  Scientific Reports · 2016 · https://doi.org/10.1038/srep26801

• Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

  The Lancet Neurology · 2006 · 10.1016/s1474-4422(06)70355-6

• Increased Sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Mouse Model of Huntington's Disease

  Neuron · 2002 · https://doi.org/10.1016/s0896-6273(02)00615-3

Current projects

No projects listed.